A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
Astellas Pharma Global Development, Inc. · Prostate Cancer
Phase 2
Recruiting
900
2026-07
Evidence dashboardStudies since 2004Updated Jul 31, 2026
LeuprolideClinical Trials.
A source-linked view of every Leuprolide study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 75
- Recruiting
- 29
- Completed
- 12
- Terminated
- 1
- Results posted
- 11
- Average enrollment
- 381
- Countries
- 63
- Highest phase
- Phase 4
Largest indexed study
4,170 participants · NCT04961996 →Developer / research origin
Multiple
Evidence summary
Activity is not efficacy.
Leuprolide appears in 75 indexed studies: 29 recruiting, 12 completed and 11 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Leuprolide is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
National Cancer Institute (NCI) · Locally Advanced Salivary Gland Carcinoma · Metastatic Salivary Gland Carcinoma
Phase 2
Active, not recruiting
21
2026-07
Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Determined by Questionnaires
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) · Systemic Lupus Erythematosus (Sle) · Primary Ovarian Insufficiency (Poi)
Not applicable
Recruiting
100
2026-07
RecoverPC: Relugolix vs GnRH Agonist in Quality of Life
Dana-Farber Cancer Institute · Prostate Cancer · Prostatic Neoplasms
Phase 2
Recruiting
110
2026-07
A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty
LG Chem · Central Precocious Puberty
Phase 4
Recruiting
43
2026-07
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
ECOG-ACRIN Cancer Research Group · Prostate Carcinoma
Phase 3
Active, not recruiting
27
2026-07
Showing 6 of 62 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects With Central Precocious Puberty
Foresee Pharmaceuticals Co., Ltd. · Puberty; Precocious, Central
Phase 3
Completed
94
2026-07
Long Acting LHRH Versus Short Acting LHRH in the Treatment of Prostate Cancer
University of British Columbia · Prostate Cancer
Not applicable
Completed
100
2026-07
High-Dose Brachytherapy in Treating Patients With Prostate Cancer
Stanford University · Prostate Adenocarcinoma · Stage I Prostate Cancer
Not applicable
Completed
146
2026-07
Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery
NRG Oncology · Stage I Prostate Adenocarcinoma AJCC v7 · Stage II Prostate Adenocarcinoma AJCC v7
Phase 2 / Phase 3
Completed
612
2026-06
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Praful Ravi, MB BCHir, MRCP · Metastatic Prostate Cancer · Non-metastatic Prostate Cancer
Phase 1
Completed
9
2026-06
Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
Sumitomo Pharma America, Inc. · Prostate Cancer
Phase 3
Completed
387
2026-06
Showing 6 of 12 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Skeletal Health and Bone Marrow Composition Among Youth
Amy DiVasta, MD · Gender Dysphoria in Children · Puberty
Not applicable
Terminated
78
2026-04
Full study index
Search Leuprolide trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
75 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 7108499 ↗Friedman RC, Clarkin JF, Corn R, Aronoff MS, Hurt SW, Murphy MC. DSM-III and affective pathology in hospitalized adolescents. J Nerv Ment Dis. 1982 Sep;170(9):511-21. doi: 10.1097/00005053-198209000-00001. No abstract available.Linked from NCT05567198PMID 24081299 ↗Kiriakidou M, Cotton D, Taichman D, Williams S. Systemic lupus erythematosus. Ann Intern Med. 2013 Oct 1;159(7):ITC4-1. doi: 10.7326/0003-4819-159-7-201310010-01004. No abstract available.Linked from NCT05567198PMID 4555317 ↗Stamenovic B. [Effect of increased chloride on the spontaneous release of acetylcholine in the neuromuscular synapses of amphibia poisoned with Clostridium toxin Type A]. Vojnosanit Pregl. 1972 Mar;29(3):139-44. No abstract available. Serbian.Linked from NCT05567198PMID 42070324 ↗Erfani H, Martynova A, Matsuzaki S, Matsuo K, Roman LD, Sood AK, Kurnit KC, Westin SN. Androgen receptor as a therapeutic target in endometrial cancer: a narrative review. Int J Gynecol Cancer. 2026 Jun;36(6):104698. doi: 10.1016/j.ijgc.2026.104698. Epub 2026 Apr 11.Linked from NCT06169124PMID 36710203 ↗Montgomery B, Mostaghel EA. Neoadjuvant Therapy Prior to Prostatectomy: Is the Glass Half Full? Eur Urol. 2023 Jun;83(6):519-520. doi: 10.1016/j.eururo.2023.01.021. Epub 2023 Jan 27. No abstract available.Linked from NCT05498272PMID 42333826 ↗Freedland SJ, De Giorgi U. Enzalutamide in biochemically recurrent prostate cancer: key findings from subsequent analyses of EMBARK and their implications in clinical practice. Future Oncol. 2026 Jun;22(14):1593-1600. doi: 10.1080/14796694.2026.2676559. Epub 2026 Jun 23.Linked from NCT02319837PMID 41364813 ↗Shore ND, Gleave M, De Giorgi U, Rannikko A, Pieczonka CM, Sridharan S, Brasso K, Woo HH, Gomez Caamano A, Saranchuk JW, Nordquist LT, Ferreira U, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. Treatment of High-Risk Biochemically Recurrent Prostate Cancer With Enzalutamide in Combination With Leuprolide: Secondary End Points From the EMBARK Trial. J Urol. 2026 May;215(5):512-525. doi: 10.1097/JU.0000000000004890. Epub 2025 Dec 9.Linked from NCT02319837PMID 41349040 ↗Shore ND, De Giorgi U, Tutrone RF, Bailen JL, Roos EPM, Kliment J, Marx G, Karsh LI, Ramirez-Backhaus M, Uchio EM, Supiot S, Tang Y, Rosbrook B, Haas GP, Rosales M, Zohren F, Tarazi J, Freedland SJ. Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. J Urol. 2026 Apr;215(4):396-407. doi: 10.1097/JU.0000000000004879. Epub 2025 Dec 5.Linked from NCT02319837
Related pages
Keep researching Leuprolide.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.